LARA FLYNN

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients. The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace. Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines. Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs. Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Pennsylvania is a global leader in researching and developing new therapies, cures, and devices that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. Life Sciences PA works annually with its Federal Policy Committee and national partners to develop a set of policy issues and recommendations that will support and enhance the countrys life sciences ecosystem and maintains Pennsylvanias leadership in life sciences innovation. As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access.

Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients. Life Sciences PA joined Pennsylvania patients and researchers at the Rally for Medical Research encouraging Congress to support the highest possible appropriation increase recommended by the medical research community and to complete the FY2026 appropriations process in a timely manner to avoid additional disruptions to the life sciences ecosystem.

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients. Life Sciences PA joined Pennsylvania patients and researchers at the Rally for Medical Research encouraging Congress to support the highest possible appropriation increase recommended by the medical research community and to complete the FY2026 appropriations process in a timely manner to avoid additional disruptions to the life sciences ecosystem.

Previously, Section 174 of the US Tax code allowed businesses to deduct research and experimentation expenses in the same taxable year in which they occurred. Currently, businesses must amortize such deductions over five years for domestic expenditures or over 15 years for foreign expenditures. Life Sciences Pennsylvania supports the American Innovation and R&D Competitiveness Act which will fix this issue that adversely affects adversely affects many of our pre-revenue and early stage member companies. In a bipartisan manner, the majority of the Pennsylvania delegation has previously voted in favor of the repeal of Section 174 so that smaller companies can resume investing maximal resources in critical R&D.

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients. The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace. Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines. Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs. Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.

American medical device manufactures are subject to rigorous regulations. The FDA must approve any shift in manufacturing sites to ensure continued product safety and effectiveness. Relocating operations involves revalidating all processes and equipment, a complex undertaking that can take years. Delays in this process could threaten timely access to essential technologies, especially for patients with unmet medical needs. The medical device presence in Pennsylvania is significant, supporting high-quality jobs in manufacturing and research and development in Pittsburgh, Philadelphia, Bellefonte, Bethlehem and across the Commonwealth. Employment in the sector has outpaced general manufacturing job growth in recent years, thanks in part to sound tax policies such as the repeal of the medical device tax and recent legislative reforms. Careers in medical device manufacturing also tend to offer higher wages than other manufacturing sectors. The strength of the American medical device sector is a strategic asset. Our ability to manage complex supply chains ensures that American patients have access to the medical technologies they need, when they need them.

Pennsylvania is a global leader in researching and developing new therapies, cures, and devices that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. Life Sciences PA works annually with its Federal Policy Committee and national partners to develop a set of policy issues and recommendations that will support and enhance the countrys life sciences ecosystem and maintains Pennsylvanias leadership in life sciences innovation. As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access.

Pennsylvania is a global leader in researching and developing new therapies, cures, and devices that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. Life Sciences PA works annually with its Federal Policy Committee and national partners to develop a set of policy issues and recommendations that will support and enhance the countrys life sciences ecosystem and maintains Pennsylvanias leadership in life sciences innovation. As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access.

Previously, Section 174 of the US Tax code allowed businesses to deduct research and experimentation expenses in the same taxable year in which they occurred. Currently, businesses must amortize such deductions over five years for domestic expenditures or over 15 years for foreign expenditures. Life Sciences Pennsylvania supports the American Innovation and R&D Competitiveness Act which will fix this issue that adversely affects adversely affects many of our pre-revenue and early stage member companies. In a bipartisan manner, the majority of the Pennsylvania delegation has previously voted in favor of the repeal of Section 174 so that smaller companies can resume investing maximal resources in critical R&D.

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. In 2023, Pennsylvania research institutions and small companies received more than $2 billion in NIH funding. This critical funding provides our ecosystem with foundational resources for biomedical innovation. It is complemented by significant private funding necessary to advance basic scientific research into safe, usable, and effective medicines. In fact, a 2022 report found that [private]industry accounts for nearly two-thirds of U.S. medical and health investment in R&D and the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D As a critical component of this ecosystem, it is essential we continue to expand support for the National Institutes of Health to ensure the United States - and Pennsylvania - remain a global leader in researching and developing new therapies, cures, and technologies that help patients live longer, healthier lives. Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. Specifically, we encourage our membership to contact their members of Congress through our Advocacy Action Center regarding the newly announced 15% indirect cost rate that immediately applies to all new and existing NIH grants. The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients

Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients. The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace. Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines. Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs. Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.

Its important that when discussing patient access, we also highlight the drug pricing supply chain in the United States. While much attention is focused on the cost of prescription medicines, which account for approximately 10-14% of nationwide health care costs - a number thats remained consistent for decades - the real issue is the out-of-pocket costs borne by patients. The cost of medicines is the cause of much debate by the public and elected officials and determining who pays for what medicines and at what cost is an important discussion to have. Life Sciences PA believes all parts - pharmacy benefit managers (PBMs), health insurance companies, pharmacies, healthcare providers, distributors and manufacturers - of our complex drug pricing system have a role to play in this debate. It is incumbent upon all of us to ensure that all parts of the prescription drug supply chain are acting in good faith and working to keep costs, especially those out-of-pocket costs borne by the patient, at an accessible level. Life Sciences PA is committed to educating legislators on how insurance benefit design and various actors in the drug pricing supply chain can affect the out-of-pockets costs patients pay at the pharmacy. As noted above, the drug pricing, payment and distribution system is complex and includes many stakeholders. Life Sciences PA believes that all those stakeholders must be included in any, and all, discussions around lowering the cost of prescription medicines.

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. In 2023, Pennsylvania research institutions and small companies received more than $2 billion in NIH funding. This critical funding provides our ecosystem with foundational resources for biomedical innovation. It is complemented by significant private funding necessary to advance basic scientific research into safe, usable, and effective medicines. In fact, a 2022 report found that [private]industry accounts for nearly two-thirds of U.S. medical and health investment in R&D and the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D As a critical component of this ecosystem, it is essential we continue to expand support for the National Institutes of Health to ensure the United States - and Pennsylvania - remain a global leader in researching and developing new therapies, cures, and technologies that help patients live longer, healthier lives. Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. Specifically, we encourage our membership to contact their members of Congress through our Advocacy Action Center regarding the newly announced15% indirect cost rate that immediately applies to all new and existing NIH grants. The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive.

Previously, Section 174 of the US Tax code allowed businesses to deduct research and experimentation expenses in the same taxable year in which they occurred. Currently, businesses must amortize such deductions over five years for domestic expenditures or over 15 years for foreign expenditures. Life Sciences Pennsylvania supports the American Innovation and R&D Competitiveness Act which will fix this issue that adversely affects adversely affects many of our pre-revenue and early stage member companies. In a bipartisan manner, the majority of the Pennsylvania delegation has previously voted in favor of the repeal of Section 174 so that smaller companies can resume investing maximal resources in critical R&D.

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States. In 2023, Pennsylvania research institutions and small companies received more than $2 billion in NIH funding. This critical funding provides our ecosystem with foundational resources for biomedical innovation. It is complemented by significant private funding necessary to advance basic scientific research into safe, usable, and effective medicines. In fact, a 2022 report found that [private]industry accounts for nearly two-thirds of U.S. medical and health investment in R&D and the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D As a critical component of this ecosystem, it is essential we continue to expand support for the National Institutes of Health to ensure the United States - and Pennsylvania - remain a global leader in researching and developing new therapies, cures, and technologies that help patients live longer, healthier lives. Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. Specifically, we encourage our membership to contact their members of Congress through our Advocacy Action Center regarding the newly announced15% indirect cost rate that immediately applies to all new and existing NIH grants. The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients

Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients. The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace. Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines. Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs. Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.

Its important that when discussing patient access, we also highlight the drug pricing supply chain in the United States. While much attention is focused on the cost of prescription medicines, which account for approximately 10-14% of nationwide health care costs - a number thats remained consistent for decades - the real issue is the out-of-pocket costs borne by patients. The cost of medicines is the cause of much debate by the public and elected officials and determining who pays for what medicines and at what cost is an important discussion to have. Life Sciences PA believes all parts - pharmacy benefit managers (PBMs), health insurance companies, pharmacies, healthcare providers, distributors and manufacturers - of our complex drug pricing system have a role to play in this debate. It is incumbent upon all of us to ensure that all parts of the prescription drug supply chain are acting in good faith and working to keep costs, especially those out-of-pocket costs borne by the patient, at an accessible level. Life Sciences PA is committed to educating legislators on how insurance benefit design and various actors in the drug pricing supply chain can affect the out-of-pockets costs patients pay at the pharmacy. As noted above, the drug pricing, payment and distribution system is complex and includes many stakeholders. Life Sciences PA believes that all those stakeholders must be included in any, and all, discussions around lowering the cost of prescription medicines.

Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration Life Sciences Pennsylvania supports Federal incentivize investment in the R&D of therapies and cures for rare disorders as well as policies to improve public health and pandemic preparedness including anti-microbial resistance, PAHPA reauthorization, and substance use disorder crisis. H.R. 7384, the Creating Hope Reauthorization Act of 2024 would reauthorize the Rare Pediatric Disease Priority Review Voucher Program (PPRV). The program incentivizes the development of novel therapies to treat pediatric rare diseases. By September of 2024, the Pediatric Priority Review Voucher will expire, and Life Sciences Pennsylvania supports the reauthorization of this crucial legislation.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.

Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.

Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation.

Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Express concern with CMS via comment letter on their TCET rule implementation Express concern with CMS MAC recent LCD determination to eliminate Medicare coverage of advanced wound treatment products.

Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration

Support reintroduction of the VALID Act (previously HR 4128)

Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Urge support funding increases for the National Institutes of Health

Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act Protecting Medicare Part D and Part B Increases in NIH funding and Reauthorization of SBIR/STTR Programs Support legislation that improves public health - e.g. PAHPA Reauthorization and PASTEUR Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR1691 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements Repealing R&D Tax Amortization - S866